Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Evidence for distinct human cancer stem cells (CSCs) remains contentious and the degree to which different cancer cells contribute to propagating malignancies in patients remains unexplored. In low- to intermediate-risk myelodysplastic syndromes (MDS), we establish the existence of rare multipotent...

Descripció completa

Dades bibliogràfiques
Autors principals:	Woll, P, Kjällquist, U, Chowdhury, O, Doolittle, H, Wedge, D, Thongjuea, S, Erlandsson, R, Ngara, M, Anderson, K, Deng, Q, Mead, A, Stenson, L, Giustacchini, A, Duarte, S, Giannoulatou, E, Taylor, S, Karimi, M, Scharenberg, C, Mortera-Blanco, T, Macaulay, I, Clark, SA, Dybedal, I, Josefsen, D, Fenaux, P, Hokland, P, Holm, MS, Cazzola, M, Malcovati, L, Tauro, S, Bowen, D, Boultwood, J, Pellagatti, A, Pimanda, J, Unnikrishnan, A, Vyas, P, Göhring, G, Schlegelberger, B, Tobiasson, M, Kvalheim, G, Constantinescu, SN, Nerlov, C, Nilsson, L, Campbell, P, Sandberg, R, Papaemmanuil, E, Hellström-Lindberg, E, Linnarsson, S, Jacobsen, S
Format:	Journal article
Idioma:	English
Publicat:	Cell Press 2014

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Ítems similars